%PDF-1.4
%
51 0 obj
<>
endobj
48 0 obj
<>
endobj
109 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-07-29T18:22:41Z
2024-03-18T23:48:44-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-18T23:48:44-07:00
application/pdf
Heather
2002-721.sept
uuid:76754dda-1dd2-11b2-0a00-590827edca00
uuid:76754ddc-1dd2-11b2-0a00-380000000000
endstream
endobj
37 0 obj
<>
endobj
38 0 obj
<>
endobj
52 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 23 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 25 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 31 0 R/Type/Page>>
endobj
127 0 obj
[131 0 R]
endobj
128 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(blood of patients with rheumatoid arthritis: correlations with)Tj
0 -1.25 TD
[(disease activity)64.8 (. J Rheumatol 1990:17:597-602.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (T)69.9 (ebib JG, Letroublon MC, Bienvenu J, Bouvier M. sIL-2R levels in)]TJ
2.1381 -1.25 Td
(rheumatoid arthritis: poor correlation with clinical activity is due to)Tj
T*
(part to disease duration. Br J Rheumatol 1995;34:1037-40.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Reibnegger G, Egg D, Fuchs D, et al. Urinary neopterin reflects)]TJ
2.175 -1.25 Td
[(clinical activity in patients with rheumatoid arthritis. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1986;29:1063-70.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875.1 (Hannonen P)110.7 (,)-0.1 ( )17.7 (T)35 (ikanoja S, Hakola M, Mottonen )17.7 (T)74 (,)-0.1 ( )17.7 (V)59.8 (iinikka L, Oka)]TJ
2.175 -1.25 Td
[(M. Urinary neopterin index as a measure of rheumatoid activity)64.8 (.)]TJ
T*
(Scand J Rheumatol 1986;15:148-52.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Nassonov EL, Samsonov MY)128.8 (, )17.7 (T)35 (ilz GP)110.7 (, et al. Soluble adhesion)]TJ
2.175 -1.25 Td
(molecules in rheumatoid arthritis. Rheumatology 2000;39: 808-10.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated)]TJ
2.175 -1.25 Td
(production of neopterin. Release from macrophages primarily under)Tj
T*
(control of interferon? J Exp Med 1984;160:310-6. )Tj
-2.175 -1.25 Td
[(16.)-875.1 (Fuchs D, Hausen )54.8 (A, Reibnegger G, )17.7 (W)79.9 (erner ER, Dierich MP)110.7 (,)]TJ
2.175 -1.25 Td
[(W)79.9 (achter H. Neopterin as a marker for activated cell-mediated)]TJ
T*
[(immunity: application in HIV)-257.3 (infection. Immunol )17.7 (T)69.9 (oday)]TJ
0 Tc 0 Tw T*
(1988;9:150-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (Carlin JM, Ozaki )36.8 (Y)128.9 (, Byrne GI, Brown RR, Borden EC. Interferons)]TJ
2.175 -1.25 Td
(and indoleamine 2,3-dioxygenase: role in antimicrobial and )Tj
T*
[(antitumor ef)17.7 (fects. Experientia 1989;45:535-41.)]TJ
-2.175 -1.25 Td
[(18.)-875.1 (Fuchs D, M\232ller )54.8 (AA, Reibnegger G, St\232ckle E, )17.7 (W)79.9 (erner ER,)]TJ
2.175 -1.25 Td
[(W)79.9 (achter H. Decreased serum tryptophan in patients with HIV)91.7 (-1)]TJ
T*
(infection correlates with increased serum neopterin and with )Tj
T*
[(neurologic/psychiatric symmptoms. J )54.8 (Acquir Immune Def Syndr)]TJ
0 Tc 0 Tw T*
(1990;3:873-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(19.)-875.1 (W)39.8 (idner B, )17.7 (W)79.9 (erner ER, Schennach H, )17.7 (W)79.9 (achter H, Fuchs D.)]TJ
2.175 -1.25 Td
(Simultaneous measurement of serum tryptophan and kynurenine by)Tj
T*
(HPLC. Clin Chem 1997;43:2424-6.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (Denz H, Orth B, )17.7 (W)79.9 (eiss G, et al. )17.7 (W)79.9 (eight loss in patients with )]TJ
2.175 -1.25 Td
(hematological neoplasias is associated with immune system )Tj
T*
(stimulation. Clin Investig 1993;71:37-41.)Tj
-2.175 -1.25 Td
[(21.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
(of rheumatoid arthritis. 1988;31:315-24.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Steinbrocker O, )17.7 (T)35 (raeger CH, Battermann RC. )17.7 (Therapeutic criteria)]TJ
2.175 -1.25 Td
[(in rheumatoid arthritis, JAMA)-220.2 (1949;140:659-62.)]TJ
30.825 47.5 Td
[(23.)-875.1 (W)79.9 (erner ER, )17.7 (W)79.9 (erner)19.7 (-Felmayer G, Fuchs D, Hausen )54.8 (A, Reibnegger)]TJ
2.175 -1.25 Td
[(G, )17.7 (W)79.9 (achter H. Parallel induction of tetrahydrobiopterin )]TJ
T*
(biosynthesis and indoleamine 2,3-dioxygenase activity in human)Tj
T*
(cells and cell lines by interferon-gamma. Biochem J )Tj
0 Tc 0 Tw T*
(1989;262:861-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Houpt JB. )17.7 (T)35 (ryptophan: new questions for an old amino acid. )]TJ
2.175 -1.25 Td
(J Rheumatol 1990;17:1431-4.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Maerker)19.7 (-Alzer G, Diemer O, Strumper R, Rohe M. Neopterin)]TJ
2.175 -1.25 Td
(production in inflamed knee joints: high levels in synovial fluids.)Tj
T*
(Rheumatol Int 1986;6:151-4.)Tj
-2.175 -1.25 Td
[(26.)-875.1 (Altindag ZZ, Sahin G, Inaninci F)79.7 (, Hascelik Z. Urinary neopterin)]TJ
2.175 -1.25 Td
(excretion and dihydropteridine reductase activity in rheumatoid)Tj
T*
[(arthritis. Rheumatol Int 1998;18:107-1)36.8 (1.)]TJ
-2.175 -1.25 Td
[(27.)-875.1 (Pfef)17.7 (ferkorn ER. Interferon gamma blocks the growth of)]TJ
2.175 -1.25 Td
[(T)69.9 (oxoplasma gondii in human fibroblasts by inducing the host cells)]TJ
T*
[(to degrade tryptophan. Proc Natl )54.8 (Acad Sci USA)-220.2 (1984;81:908-12. )]TJ
-2.175 -1.25 Td
[(28.)-875.1 (Burke F)79.7 (, Knowles RG, East N, Balkwill FR. )17.7 (The role of)]TJ
2.175 -1.25 Td
(indoleamine 2,3-dioxygenase in the anti-tumour activity of human)Tj
T*
[(interferon-gamma in vivo. Int J Cancer 1995;60:1)36.8 (15-22.)]TJ
-2.175 -1.25 Td
[(29.)-875.1 (Munn, DH, Shafizadeh E, )54.8 (Attwood JT)73.9 (, Bondarev I, Pashine )54.8 (A,)]TJ
2.175 -1.25 Td
[(Mellor )54.8 (AL. Inhibition of )17.7 (T)91.9 (-cell proliferation by macrophage )]TJ
T*
(tryptophan catabolism. J Exp Med 1999;189:1663-72.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (Mellor )54.8 (AL, Munn DH. )17.7 (T)35 (ryptophan catabolism and )17.7 (T)91.9 (-cell tolerance:)]TJ
2.175 -1.25 Td
[(Immunosuppression by starvation? Immunol )17.7 (T)69.9 (oday )]TJ
0 Tc 0 Tw T*
(1999;20:469-73.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(31.)-875.1 (Lemmel EM, Franke M, Gaus )17.7 (W)91.9 (, et al. Results of a phase-II )]TJ
2.175 -1.25 Td
(clinical trial on treatment of rheumatoid arthritis with recombinant)Tj
T*
(interferon-gamma. Rheumatol Int 1987;7:127-32.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (Houpt JB, Ogryzlo MA, Hunt M. )17.7 (T)35 (ryptophan metabolism in man)]TJ
2.175 -1.25 Td
(\(with special reference to rheumatoid arthritis and scleroderma\).)Tj
T*
[(Semin )54.8 (Arthritis Rheum 1973;2:333-53.)]TJ
-2.175 -1.25 Td
[(33.)-875.1 (Coblyn JS, Shadick N, Helfgott S. Leflunomide-associated weight)]TJ
2.175 -1.25 Td
[(loss in rheumatoid arthritis. )54.8 (Arthritis Rheum 2001;44:1048-51.)]TJ
-2.175 -1.25 Td
[(34.)-875.1 (W)39.8 (idner B, Laich )54.8 (A, Sperner)19.7 (-Unterweger B, Ledochowski M, Fuchs)]TJ
2.175 -1.25 Td
(D. Neopterin production, tryptophan degradation, and mental)Tj
T*
[(depression. )17.7 (What is the link? Brain Behav Immun 2002;16:580-5.)]TJ
-2.175 -1.25 Td
[(35.)-875.1 (Huang )54.8 (A, Fuchs D, )17.7 (W)39.8 (idner B, Glover C, Henderson DC, )54.8 (Allen-)]TJ
2.175 -1.25 Td
[(Mersh )17.7 (TG. )17.7 (T)35 (ryptophan decrease in advanced colorectal cancer)]TJ
T*
(correlates with immune activation and impaired quality of life. Br )Tj
T*
(J Cancer 2002;86:1691-6.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Schr)36.8 (oecksnadel, et al: T)54.8 (ryptophan degradation in RA)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(1939)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 18, 2024 from )Tj
ET
endstream
endobj
31 0 obj
<>stream
8;Z\6!HQ(3#ikq,j?)ZR7M7USdOs3j46r=nF_hHfjL?ior%Zh3^4"_]2YO`O(giZD
rNX5jG/]Ubh#qNj=ko?uYh[-Nd<9cc5&bJ5:n'gc/N@N51hIRe13>HuVTfuoiiM-Y
@Y\Y(K&&To@.KtH_n`'f
.4[%E\Wk=@IgX6TVSR6+]o!Da9$Yk.:]Og%N;'%q%(j/n/WCd4f(Dbh4HdDMF!6J!P[Oom-?roXnWS:(:?CmpJ"oeEPUJin3Wn-%RKA(5!M
H:7\nVE'B$!HCZLYM?n?HX-!g$*"-l9NdsQ(Z%6H^J''#0!r[*dG0!Mg5:rLNHjP5
/ln/k&%W>=X=F'F'rP)3Q6@&:(BhGGbfE5\RF@X@Os9(g^.!q5E')2;@u/KOJjD%D
!K$'dU!f/HXQLAe7>C_&V0B]fYm"JY6HQL[
OHd#7R>:jT8d/oUpt;ij8+\1poL$@F4[5V1$O[=M$O[=M$bm!p+1E(IZ$9JpnP\`E
DLQ`u@rD6`Hjp'2K7C$~>
endstream
endobj
35 0 obj
[/Indexed/DeviceRGB 255 34 0 R]
endobj
34 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
59 0 obj
<>
endobj
54 0 obj
<>
endobj
98 0 obj
<>
endobj
114 0 obj
<>
endobj
55 0 obj
<>
endobj
91 0 obj
<>stream
HUiPSY~-MH3̨
nբ ",6 @%$ @4*66펨-*c=tU=KL35gT}u{ߩ1c#q;m![WRUɼ#o[gqF+,2v}ca8oa̸Yأ( چ=ZpǺEl8NնZ峍&%$
9ˏfߺo㸜""J=Hg
r2ݬp3w7X0#6q? 4.'65~5?3 2x^l+{,0ksC6FccCbXF`$ƒG3F sxk%k&*ʉRZMdffkv|I_-
,I`7/YYZɬ)mbm.zێj7LyjZΡtrs89p؆1+NvBr